Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both
Research article published in Journal of the neurological sciences (2017)
Abstract
INTRODUCTION: Data are limited on the optimal management of cryptogenic TIA/stroke patients with a patent foramen ovale (PFO)±inter-atrial septal aneurysm (IASA), especially with an inherited thrombophilia. METHODS: Prospectively-collected data on TIA/ischaemic stroke patients with PFO, IASA or both who received 'goal-directed secondary-prevention medical treatment' were analysed. All patients had trans-oesophageal echocardiography, anti-nuclear, anti-cardiolipin, anti-beta 2 glycoprotein I antibodies, rheumatoid factor, lupus anticoagulant, protein C&S, anti-thrombin, factor VIII activity, activated protein C resistance, Factor V Leiden, prothrombin gene and MTHFR-c.677C>T mutation screening. ENA and homocysteine were assessed in the latter study period. RESULTS: Eighty-three patients were recruited. Mean follow-up: 48.1months. Forty-seven patients (56.6%) had an isolated PFO, 32 (38.6%) a PFO and an IASA, and 4 (4.8%) an IASA alone. Eighteen (21.7%) had ≥1 abnormality on thrombophilia screening. The most important abnormalities which lead to treatment changes in 11 patients (13.3%) were primary anti-phospholipid syndrome (N=3; 3.6%), protein S deficiency (N=2; 2.4%) hyper-homocysteinaemia (N=6/72 screened, 8.3%). Four patients (4.8%) opted for PFO closure: two with protein S deficiency, and two with no identified thrombophilia. Seven (8.4%) had recurrent TIA/ischaemic stroke during follow-up (overall annualised incidence: 2.1%), of whom five had a PFO alone and two a PFO and IASA. DISCUSSION: Comprehensive arterial and venous thrombophilia screening is warranted in TIA/ischaemic stroke patients with a PFO±IASA, is conclusively abnormal in over a fifth, and informed important decision-making regarding individualised therapy in 13.3% of patients. The incidence of recurrent vascular events in this population is low on optimal, personalised secondary-prevention treatment, even with an underlying thrombophilia.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Data are limited on the optimal management of cryptogenic TIA/stroke patients with a patent foramen ovale (PFO)±inter-atrial septal aneurysm (IASA), especially with an inherited thrombophilia. Prospectively-collected data on TIA/ischaemic stroke patients with PFO, IASA or both who received 'goal-directed secondary-prevention medical treatment' were analysed.
Warum dies für die Hirudotherapie relevant ist
Diese prospektive Beobachtungsstudie begleitete 83 Patienten mit TIA/ischämischem Schlaganfall, die ein offenes Foramen ovale und/oder ein interatriales Septumaneurysma aufwiesen und ein umfassendes arterielles und venöses Thrombophilie-Screening durchliefen; bei mehr als einem Fünftel lag mindestens eine Auffälligkeit vor, das Screening veränderte das Management bei 13,3% der Patienten, und die Rate wiederkehrender vaskulärer Ereignisse war niedrig (annualisierte Inzidenz 2,1%) unter individualisierter Sekundärprävention. Für ASH ist dies der breiteren Evidenzlandschaft zu Thrombose/Antikoagulation zuzuordnen und berührt die Blutegeltherapie nicht direkt: Die Arbeit dokumentiert, wie erbliche und erworbene Thrombophilien antithrombotische Entscheidungen prägen — dasselbe klinische Feld, in dem natürliche antithrombotische Wirkstoffe wie das aus Blutegeln gewonnene hirudin konzeptionell angesiedelt sind. Der Vorbehalt ist, dass es sich um eine monozentrische Beobachtungskohorte mit bescheidener Stichprobengröße handelt, die auf das Management von PFO/IASA-Schlaganfällen fokussiert ist, die Hirudotherapie nicht erwähnt, und deren Befunde zur Screening-Ausbeute und zum Rezidiv spezifisch für diese ausgewählte Population sind.
Zitation
Clinical outcomes and a high prevalence of abnormalities on comprehensive arterial and venous thrombophilia screening in TIA or ischaemic stroke patients with a patent foramen ovale, an inter-atrial septal aneurysm or both.
Lim ST et al. · Journal of the neurological sciences, 2017
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: May 28, 2026 · Letzte Aktualisierung der Website: June 18, 2026